Enovis (NYSE:ENOV) Issues FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.520-3.730 for the period, compared to the consensus estimate of 3.540. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Analyst Ratings Changes

ENOV has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Wells Fargo & Company decreased their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Evercore set a $32.00 price target on shares of Enovis in a report on Monday, July 6th. William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They issued an “outperform” rating on the stock. Finally, UBS Group reaffirmed a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.00.

Enovis Trading Down 12.2%

Shares of ENOV traded down $3.69 during mid-day trading on Thursday, reaching $26.50. The company’s stock had a trading volume of 3,126,919 shares, compared to its average volume of 1,052,200. Enovis has a 52 week low of $19.14 and a 52 week high of $34.28. The stock has a market cap of $1.53 billion, a PE ratio of -1.33 and a beta of 1.34. The company’s fifty day moving average price is $24.54 and its two-hundred day moving average price is $23.95. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter last year, the firm earned $0.79 EPS. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts predict that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction on Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 4,200 shares of company stock worth $92,084 in the last ninety days. 2.90% of the stock is owned by corporate insiders.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q2 earnings exceeded expectations: Enovis reported adjusted EPS of $0.90, above the $0.83–$0.85 analyst estimates and up from $0.79 a year earlier. Revenue increased 3.2% year over year to $582.8 million, narrowly beating the $581.8 million consensus. Enovis Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Reconstructive business remained strong: Reconstructive sales grew 8% on a reported basis and 6% organically, helping drive total second-quarter sales growth of 3% reported and 5% organically. Management reaffirmed its full-year 2026 revenue, adjusted EBITDA, adjusted EPS and free-cash-flow-conversion targets. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: Analyst support increased: BTIG Research raised its Enovis price target to $40 from $39 and assigned a Buy rating, indicating substantial potential upside from recent trading levels. BTIG Raises Enovis Price Target
• Neutral Sentiment: 2026 guidance was reaffirmed: Enovis forecast revenue of approximately $2.3 billion to $2.4 billion and EPS of $3.52 to $3.73. The EPS range broadly brackets the $3.54 consensus estimate, offering limited evidence of a meaningful outlook increase.
• Negative Sentiment: Investors may have wanted stronger growth or guidance: Although profitability beat estimates, reported sales growth remained modest, and the company continues to report a negative net margin. Those factors may be overshadowing the quarterly beat and positive analyst action.

Hedge Funds Weigh In On Enovis

A number of institutional investors have recently added to or reduced their stakes in ENOV. Arax Advisory Partners bought a new position in shares of Enovis in the 4th quarter worth about $29,000. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Danske Bank A S bought a new position in shares of Enovis during the third quarter valued at approximately $64,000. iSAM Funds UK Ltd purchased a new position in shares of Enovis during the third quarter valued at approximately $80,000. Finally, Brown Brothers Harriman & Co. bought a new stake in shares of Enovis in the 3rd quarter worth approximately $90,000. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.